Qilu Pharmaceutical Co.

JINAN, China, Jan. 30, 2024 /PRNewswire/ — The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), have recently been featured in the Journal of Thoracic Oncology (Impact Factor=20.4), the … Read more

JINAN, China, June 8, 2023 /PRNewswire/ — Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023). Study One:Title: DUBHE-L-304: A randomized, double-blind, multicenter … Read more

JINAN, China, 12. Mai 2023 /PRNewswire/ — Am 8. Mai 2023 veröffentliche das Journal of Hematology & Oncology (JHO, 2022 Impact Factor von 23.168) die Ergebnisse der klinischen Phase-I-Studie des bifunktionalen Immuntherapie-Antikörpers QL1706 von Qilu Pharma (J Hematol Oncol 8. Mai 2023;16(1):50). Diese Studie ist die erste große klinische Phase-I-Studie mit QL1706 am Menschen und … Read more

-Resultados del estudio clínico de fase I del anticuerpo bifuncional PD-1/CTLA-4 Iparomlimab/Tuvonralimab de Qilu Pharma publicado en línea en Journal of Hematology & Oncology JINAN, China, 12 de mayo de 2023 /PRNewswire/ — El 8 de mayo de 2023, Journal of Hematology & Oncology (JHO, 2022 factor de impacto de 23.168) publicó los resultados del … Read more

JINAN, China, May 12, 2023 /PRNewswire/ — On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma’s immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023 May 8;16(1):50). This study is the first large Phase I clinical trial of … Read more